Kiadis no longer expects EU conditional marketing authorization for ATIR101 in 2020 Kiadis plans to refile at the conclusion of the ongoing phase 3 trial Amsterdam, The Netherlands, 17 October 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it no longer expects to receive EU conditional marketing… Continue reading Kiadis Pharma provides regulatory update on ATIR101
Author: Willem van Lawick
KIADIS UPDATES STATUS OF MARKETING AUTHORIZATION APPLICATION FOR ATIR101
28.JUNE 2019 AT 18:10:51 CET Kiadis updates status of marketing authorization application for ATIR101 Amsterdam, The Netherlands, June 28, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has received feedback from the European Medicines Agency (EMA) related to the marketing authorization… Continue reading KIADIS UPDATES STATUS OF MARKETING AUTHORIZATION APPLICATION FOR ATIR101
KIADIS PHARMA COMPLETES ACQUISITION OF CYTOSEN THERAPEUTICS, INC.
06.JUNE 2019 AT 07:30:00 CET Amsterdam, The Netherlands, June 6, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has closed the previously announced acquisition of CytoSen Therapeutics, Inc. (“CytoSen”). The transaction creates a leader in cell-based cancer immunotherapy with proprietary… Continue reading KIADIS PHARMA COMPLETES ACQUISITION OF CYTOSEN THERAPEUTICS, INC.
KIADIS SUBMITS RESPONSE TO THE EUROPEAN MEDICINES AGENCY’S DAY 180 SECOND LIST OF OUTSTANDING ISSUES
22.MAY 2019 AT 20:11:16 CET Amsterdam, The Netherlands, May 22, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted a response to the European Medicines Agency’s (EMA) second Day 180 list of outstanding issues for ATIR101. Kiadis submitted a… Continue reading KIADIS SUBMITS RESPONSE TO THE EUROPEAN MEDICINES AGENCY’S DAY 180 SECOND LIST OF OUTSTANDING ISSUES
BE THE MATCH BIOTHERAPIES® AND KIADIS PHARMA ANNOUNCE STRATEGIC COLLABORATION TO ACCELERATE PATIENT ACCESS TO HAPLOIDENTICAL STEM CELL THERAPIES
22.MAY 2019 AT 18:00:00 CET Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Kiadis Pharma N.V. (“Kiadis”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today… Continue reading BE THE MATCH BIOTHERAPIES® AND KIADIS PHARMA ANNOUNCE STRATEGIC COLLABORATION TO ACCELERATE PATIENT ACCESS TO HAPLOIDENTICAL STEM CELL THERAPIES
